Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taxodium distichum pollen is a non-standardized allergenic extract derived from the pollen of the bald cypress tree (Taxodium distichum). [2, 9] It is classified as a biologic allergen extract and is used for both the diagnosis (via percutaneous or intradermal skin testing) and treatment of allergic conditions such as allergic rhinitis and asthma. [2, 4] For treatment, it is administered as a subcutaneous injection for hyposensitization therapy, which aims to induce immune tolerance in patients allergic to bald cypress pollen. [2] The product is marketed as a sterile aqueous or glycerinated solution by companies including ALK-Abello, Inc. and Greer Laboratories, Inc. [2, 5, 6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Taxodium distichum pollen.